The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Biomimetic 3D Tissue Models for Advanced High-Throughput Drug Screening
Open accessAbstract
Most current drug screening assays used to identify new drug candidates are 2D cell-based systems, even though such in vitro assays do not adequately re-create the in vivo complexity of 3D tissues. Inadequate representation of the human tissue environment during a preclinical test can result in inaccurate predictions of compound effects on overall tissue functionality. Screening for compound efficacy by focusing on a single pathway or protein target, coupled with difficulties in maintaining long-term 2D monolayers, can serve to exacerbate these issues when using such simplistic model systems for physiological drug screening applications. Numerous studies have shown that cell responses to drugs in 3D culture are improved from those in 2D, with respect to modeling in vivo tissue functionality, which highlights the advantages of using 3D-based models for preclinical drug screens. In this review, we discuss the development of microengineered 3D tissue models that accurately mimic the physiological properties of native tissue samples and highlight the advantages of using such 3D microtissue models over conventional cell-based assays for future drug screening applications. We also discuss biomimetic 3D environments, based on engineered tissues as potential preclinical models for the development of more predictive drug screening assays for specific disease models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“3D tissue models, such as in vitro tissue-engineered disease models have shown promise for addressing the current obstacles faced with 2D in vitro cultured cells and animal models [352–356].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [354]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Engineered whole organs and complex tissues
Badylak, S. F., Weiss, D. J., Caplan, A., & Macchiarini, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60073-7 · Cited by 417 · cited 1×
“Such models would require lung-specific cells maintained in an appropriate 3D geometry and integrated with a suitable microvascular barrier to separate blood from air, as well as adequate mechanical properties to facilitate ventilation at pressure that is physiologically normal.(88) Recent developments in lung tissue…”
RetractedInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Vascular endothelial growth factor (VEGF) and its receptors
Neufeld, G., Cohen, T., Gengrinovitch, S., & Gluzman‐Poltorak, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,511
Lee, K., Silva, E. A., & Mooney, D. J. (2010) · Journal of The Royal Society Interface · doi:10.1098/rsif.2010.0223 · Cited by 1,424
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
Chong, J. J. H., Yang, X., Don, C. W., Minami, E., Liu, Y.-W., Weyers, J. J., Mahoney, W. M., Biber, B. P. V., Cook, S. M., Palpant, N. J., et al. (2014) · Nature · doi:10.1038/nature13233 · Cited by 1,404
Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389
Tissue-Engineered Lungs for in Vivo Implantation
Petersen, T. H., Calle, E. A., Zhao, L., Lee, E. J., Gui, L., Raredon, M. S. B., Gavrilov, K., Yi, T., Zhuang, Z. W., Breuer, C. K., et al. (2010) · Science · doi:10.1126/science.1189345 · Cited by 1,189
Mathers, C. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012373960-5.00335-x · Cited by 1,125
Tissue Engineering of a Differentiated Cardiac Muscle Construct
Zimmermann, W.-H., Schneiderbanger, K., Schubert, P., Didié, M., Münzel, F., Heubach, J. F., Kostin, S., Neuhuber, W. L., & Eschenhagen, T. (2002) · Circulation Research · doi:10.1161/hh0202.103644 · Cited by 917
Research works printed but not linked: 2
- Juhas, 2014, Biomimetic Engineered Muscle with Capacity for Vascular Integration and Functional Maturation In Vino, Proc. Natl. Acad. Sci. U. S. A., 111, 5508, 10.1073/pnas.1402723111 · DOI · Paper page
- Wever, 2013, Overview of Human Three-Dimensional Skin Models Used for Dermal Toxicity Assessment—Part 1, H&PC Today, 8, 18
Cited by
Sorted by citations
3D bioprinting for engineering complex tissues
Mandrycky, C., Wang, Z., Kim, K., & Kim, D. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.12.011 · Cited by 1,818
Self-citation3D printing of hydrogels: Rational design strategies and emerging biomedical applications
Li, J., Wu, C., Chu, P. K.-H., & Gelinsky, M. (2020) · Materials Science and Engineering R Reports · doi:10.1016/j.mser.2020.100543 · Cited by 899
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling
Skardal, A., Shupe, T., & Atala, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.003 · Cited by 512
Application areas of 3D bioprinting
Ozbolat, I. T., Peng, W., & Özbolat, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.006 · Cited by 364
3D bioprinting for drug discovery and development in pharmaceutics
Peng, W., Datta, P., Ayan, B., Özbolat, V., Sosnoski, D. M., & Ozbolat, I. T. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.025 · Cited by 327
Metadata
- Authors
- Nam, K.-H., Smith, A. S. T., Lone, S., Kwon, S., & Kim, D.-H.
- Affiliations
- Seoul National University (KR)
- University of Washington (US)
- Corresponding author
- Kim, Deok-Ho
- Venue
- SLAS Technology
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 20
- Issue
- 3
- Pages
- 201-215
- ISSN
- 2472-6303 (ISSN-L)
- PMC
- PMC4459652
- OpenAlex
- W1989662123
- Cited by
- 171
- References
- 123
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 11 · 2019: 18 · 2018: 25 · 2017: 16 · 2016: 20 · 2015: 9
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- SLAS TECHNOLOGY (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Heart Association (13SDG14560076)
- Muscular Dystrophy Association (MDA 255907, 255907)
- Washington State University
- University of Washington
- Korea Basic Science Institute (D34500)
- Institute for Basic Science
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR064395)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- 3D tissue models, high-throughput drug screening, preclinical drug testing, tissue engineering, disease models
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Organ Culture Techniques, Tissue Engineering, Biomimetics, Nanotechnology, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
